Who Paid My Doc
Empagliflozin and Heart failure (HFrEF)
Research payments
$3,854,860
Through program year 2021, $3,854,860 in research payments was reported against Empagliflozin and Heart failure (HFrEF), across 5,963 payments.
- Paid by (largest first)
- Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $59,988 | 38 |
| 2020 | Research | $1,591,702 | 1,872 |
| 2019 | Research | $2,203,170 | 4,053 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Harvey Serota Saint Louis, MO Named on 351 payments
- Matthew Budoff Torrance, CA Named on 217 payments
- Alexander Paraschos Burlington, NC Named on 191 payments
- Dawn Lombardo Orange, CA Named on 178 payments
- Sean Donahoe Riverhead, NY Named on 173 payments
- Barry Harris Hollywood, FL Named on 161 payments
- Cara Ann East Dallas, TX Named on 154 payments
- Adnan Malik York, PA Named on 145 payments
- Steven Lupovitch Arlington Heights, IL Named on 142 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.